
The a2 Milk Company, which sells infant milk formula and other dairy products in China, Australia, New Zealand, and the United States, has told shareholders its China infant milk formula business is recovering from a supply failure that drove customers to rival brands. At its annual meeting, the company said estimated China label offtake has recovered to about 50 per cent of pre-supply chain disruption levels, up from about 40 per cent in August 2026.
The shortfall of China label product materially hurt in-market availability during the fourth quarter of FY26 and forced a large proportion of existing users to switch to alternative brands. English label formula offtake in the same quarter was indirectly affected by a recall of USA label formula announced in May 2026.
The company said it has been focused on executing its China recovery plan. Further detail on that plan sits in pages 13-14 of its annual meeting presentation dated 19 November 2026.
Recovery is expected to be gradual rather than immediate. China label and English label sales are forecast to pick up over FY27, helped by the recent launches of two new China label products and an updated a2 Platinum product, and by a resolution of the China importation requirements currently affecting a2 Genesis.
Supporting that push will cost money. The company expects to increase marketing, particularly in the first half of FY27. That spending, combined with the slow rebuild of formula sales, means group revenue and profit will be materially weighted to the second half of the year.
a2MC expects revenue and underlying earnings to grow in FY27, supported by product innovation and new markets, continued momentum in Other Nutritionals and Liquid Milk, and improved profitability at a2 Pōkeno, its New Zealand manufacturing site.
At this stage, the company expects total infant milk formula sales to be broadly similar to FY26. Compared with FY26 on a continuing operations basis, it forecasts revenue growth of mid-single-digit per cent, with first-half revenue slightly down on the prior first half. The underlying EBITDA margin is expected to be approximately 15 per cent, with first half EBITDA materially down on the prior first half. Depreciation and amortisation is expected to be approximately $20 million, cash conversion approximately 70-80 per cent, and capital expenditure approximately $70 million.
The shift of a2 Platinum production to a2 Pōkeno is on track. One-off transformation costs, including the Platinum transition, are now expected to be about $15 million in FY27, with no further transformation costs expected in FY28.
The company also noted that the New Zealand dollar has devalued since its previous outlook. At prevailing rates, that is expected to increase group revenue and expenses, with the associated net earnings uplift offset by hedge losses.
On the risks to that guidance, the company listed the extent and rate of recovery in China formula, trading upside and downside, macroeconomic conditions, category dynamics, and competitive intensity. It also cited product and supply risks, cross-border trade, foreign exchange movements, interest rate changes, farmgate milk pricing, and other commodity prices. Regulatory risk, export and import requirements, the Middle East conflict, a2 Pōkeno transformation and transition risks, and geopolitical risks rounded out the list.
For suppliers and service providers to a2MC, the guidance signals a first half of heavy spending and soft sales, followed by a second half that will carry most of the year’s revenue and earnings. Marketing budgets will be front-loaded; the company has said it will increase marketing in the first half.
The $15 million in transformation costs and roughly $70 million in capital expenditure point to continued investment in New Zealand manufacturing through a2 Pōkeno, even as formula recovery remains uncertain. The company frames it as a range of outcomes depending on how quickly formula sales recover, which means the second-half forecast carries the weight of the year.
Source: NZX announcements

NZ Business News reports on the decisions, deals and numbers shaping New Zealand business — the companies making them, the policy and market conditions they work within, and what it means for the people running businesses here.